A hydrogen sulfide prodrug augments angiogenesis in a swine model of critical limb ischemia via a nitric oxide dependent mechanism

Introduction: Despite advances in revascularization, treatments for critical limb ischemia (CLI) have been largely unsuccessful. Hydrogen sulfide (H2S) and nitric oxide (NO), are endogenous gasotransmitters which exert potent vasodilatory and proangiogenic effects. Recent experimental evidence suggest that the proangiogenic effects of H2S are medicated in part through the NO pathway. We sought to determine whether a novel H2S prodrug, SG-1002 (Sulfagenix, Inc. Cleveland OH), increases NO production and promotes peripheral revascularization.

Source: Artery Research - November 25, 2016 Category: Cardiology Authors: Amanda M. Rushing, Amy L. Scarborough, Sarah F. Boisvert, Erminia Donnarumma, Rishi Trivedi, David J. Polhemus, David J. Lefer, Traci T. Goodchild Source Type: research